152 related articles for article (PubMed ID: 22199326)
21. Hypersensitivity reactions to transcatheter chemoembolization with cisplatin and Lipiodol suspension for unresectable hepatocellular carcinoma.
Kawaoka T; Aikata H; Katamura Y; Takaki S; Waki K; Hiramatsu A; Takahashi S; Hieda M; Kakizawa H; Chayama K
J Vasc Interv Radiol; 2010 Aug; 21(8):1219-25. PubMed ID: 20619676
[TBL] [Abstract][Full Text] [Related]
22. Initial experience with a novel desensitization strategy for carboplatin-associated hypersensitivity reactions: carboplatin-hypersensitivity reactions.
Markman M; Hsieh F; Zanotti K; Webster K; Peterson G; Kulp B; Spicel A; Belinson J
J Cancer Res Clin Oncol; 2004 Jan; 130(1):25-8. PubMed ID: 14564516
[TBL] [Abstract][Full Text] [Related]
23. Comparison of platinum concentrations in human head and neck tumours following administration of carboplatin, iproplatin or cisplatin.
Hecquet B; Caty A; Fournier C; Lefebvre JL; Adenis L
Bull Cancer; 1987; 74(4):433-6. PubMed ID: 3311237
[TBL] [Abstract][Full Text] [Related]
24. Evaluation of the incidence of carboplatin hypersensitivity reactions in cancer patients.
Navo M; Kunthur A; Badell ML; Coffer LW; Markman M; Brown J; Smith JA
Gynecol Oncol; 2006 Nov; 103(2):608-13. PubMed ID: 16797060
[TBL] [Abstract][Full Text] [Related]
25. Diagnostic and predictive value of skin testing in platinum salt hypersensitivity.
Leguy-Seguin V; Jolimoy G; Coudert B; Pernot C; Dalac S; Vabres P; Collet E
J Allergy Clin Immunol; 2007 Mar; 119(3):726-30. PubMed ID: 17258305
[TBL] [Abstract][Full Text] [Related]
26. [Safety and Efficacy of Cisplatin Treatment after Carboplatin Hypersensitivity Reactions in Gynecologic Malignancies].
Matsuoka N; Yokoyama T; Fujimoto E; Sakai M; Okame S; Shiroyama Y; Yokoyama T; Takehara K
Gan To Kagaku Ryoho; 2017 Dec; 44(13):2091-2095. PubMed ID: 29361624
[TBL] [Abstract][Full Text] [Related]
27. Clinical features of hypersensitivity reactions to carboplatin.
Markman M; Kennedy A; Webster K; Elson P; Peterson G; Kulp B; Belinson J
J Clin Oncol; 1999 Apr; 17(4):1141. PubMed ID: 10561172
[TBL] [Abstract][Full Text] [Related]
28. Meta-analysis of randomized clinical trials comparing Cisplatin to Carboplatin in patients with advanced non-small-cell lung cancer.
Hotta K; Matsuo K; Ueoka H; Kiura K; Tabata M; Tanimoto M
J Clin Oncol; 2004 Oct; 22(19):3852-9. PubMed ID: 15326195
[TBL] [Abstract][Full Text] [Related]
29. Does the platinum-free interval predict the incidence or severity of hypersensitivity reactions to carboplatin? The experience from Women and Infants' Hospital.
Schwartz JR; Bandera C; Bradley A; Brard L; Legare R; Granai CO; Dizon DS
Gynecol Oncol; 2007 Apr; 105(1):81-3. PubMed ID: 17157366
[TBL] [Abstract][Full Text] [Related]
30. In vitro drug testing of ovarian cancer using the human tumor colony-forming assay: comparison of in vitro response and clinical outcome.
Federico M; Alberts DS; Garcia DJ; Emerson J; Fanta P; Liu R; Salmon SE
Gynecol Oncol; 1994 Dec; 55(3 Pt 2):S156-63. PubMed ID: 7835801
[TBL] [Abstract][Full Text] [Related]
31. Hypersensitivity to oxaliplatin: an investigation of incidence and risk factors, and literature review.
Kim BH; Bradley T; Tai J; Budman DR
Oncology; 2009; 76(4):231-8. PubMed ID: 19246947
[TBL] [Abstract][Full Text] [Related]
32. Rapid inpatient/outpatient desensitization for chemotherapy hypersensitivity: standard protocol effective in 57 patients for 255 courses.
Lee CW; Matulonis UA; Castells MC
Gynecol Oncol; 2005 Nov; 99(2):393-9. PubMed ID: 16054201
[TBL] [Abstract][Full Text] [Related]
33. Carboplatin hypersensitivity reaction in pediatric patients with low-grade glioma: a Canadian Pediatric Brain Tumor Consortium experience.
Lafay-Cousin L; Sung L; Carret AS; Hukin J; Wilson B; Johnston DL; Zelcer S; Silva M; Odame I; Mpofu C; Strother D; Bouffet E
Cancer; 2008 Feb; 112(4):892-9. PubMed ID: 18098210
[TBL] [Abstract][Full Text] [Related]
34. Outpatient desensitization of patients with moderate (high-risk) to severe platinum hypersensitivity reactions.
Vetter MH; Khan A; Backes FJ; Bixel K; Cohn DE; Copeland LJ; Fowler JM; Salani R; Li Q; O'Malley DM
Gynecol Oncol; 2019 Feb; 152(2):316-321. PubMed ID: 30503265
[TBL] [Abstract][Full Text] [Related]
35. Carboplatin hypersensitivity reactions: re-treatment with cisplatin desensitisation.
Jones R; Ryan M; Friedlander M
Gynecol Oncol; 2003 Apr; 89(1):112-5. PubMed ID: 12694663
[TBL] [Abstract][Full Text] [Related]
36. Anaphylaxis to carboplatin following multiple previous uncomplicated courses.
Sood AK; Gelder MS; Huang SW; Morgan LS
Gynecol Oncol; 1995 Apr; 57(1):131-2. PubMed ID: 7705695
[TBL] [Abstract][Full Text] [Related]
37. A medical research council randomized trial of single agent carboplatin versus etoposide and cisplatin for advanced metastatic seminoma. MRC Testicular Tumour Working Party.
Horwich A; Oliver RT; Wilkinson PM; Mead GM; Harland SJ; Cullen MH; Roberts JT; Fossa SD; Dearnaley DP; Lallemand E; Stenning SP;
Br J Cancer; 2000 Dec; 83(12):1623-9. PubMed ID: 11104556
[TBL] [Abstract][Full Text] [Related]
38. Desensitization treatment with cisplatin after carboplatin hypersensitivity reaction in gynecologic cancer.
Abe A; Ikawa H; Ikawa S
J Med Invest; 2010 Feb; 57(1-2):163-7. PubMed ID: 20299757
[TBL] [Abstract][Full Text] [Related]
39. Cisplatin administration following carboplatin desensitization failure in primary peritoneal cancer: a brief report.
Greene DP; Ferriss JS; Jazaeri AA
Cancer Chemother Pharmacol; 2010 Jul; 66(2):265-7. PubMed ID: 19844714
[TBL] [Abstract][Full Text] [Related]
40. One year maintenance of carboplatin in patients with epithelial ovarian cancer--a phase II study.
Safra T; Kovner F; Barak N; Inbar MJ; Ron IG
Isr Med Assoc J; 2006 Jan; 8(1):27-9. PubMed ID: 16450747
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
